By Roz Sweeney, Ph.D., Nerac Analyst
Originally Published: November 17th, 2014
The FDA recently issued updated draft guidance for proposed regulatory changes affecting laboratory developed tests (LDTs). Laboratory developed tests (or LDTs) are traditionally IVDs developed and used by CLIA labs for treating or testing patients within that lab’s associated healthcare facility. They have historically fallen under FDA enforcement discretion, under the rationale that they fall within the practice of medicine, which is not regulated by the FDA. (While the specific tests are exempt, the labs are regulated under the Clinical Laboratory Improvements Amendment of 1988.)
Over the past 30-40 years, LDT’s have evolved considerably as medicine has gotten more complex. The FDA believes that the claims of certain LDTs are not adequately supported with evidence and that certain LDTs may lack appropriate controls yielding erroneous results. The FDA is aware of harm caused by faulty LDTs. For example, the Agency is aware of harm caused by biomarker tests for early detection of ovarian cancer. In this case, patients received inappropriate treatments or even harmful treatments as a result of these tests.
Other reasons for the need for increased oversight include LDT’s being used on larger populations (e.g. outside of the local healthcare facility) and in situations where more stringently regulated devices exist (e.g. same indication and use as PMA approved devices). The proposed regulations are intended to even the playing field in safety, efficacy, and performance of LDT’s with class I, II, III IVDs.
- In Vitro Diagnostics - Upcoming Regulatory Developments in the U.S. and European Union: Are You Ready for the Transition?57Join Nerac Regulatory analysts Roz Sweeney, Ph.D. and Donna Mitchell-Magaldi for this powerful discussion designed to give you the insights and information you need on the new EU/FDA regulatory proposals/guidances and how they will be implemented by the agencies!! It is imperative that IVD manufacturers prepare for upcoming/new regulatory changes in both the EU and US.…
- 54By Roz Sweeney, Ph.D., Nerac Analyst Originally Published: September 19th, 2014 Will Laboratory-developed tests (LDTs) require FDA marketing approval? Laboratory-developed tests (LDTs) are in vitro diagnostic tests typically used within a single-institution’s CLIA lab. The FDA exempted clinical laboratories from registration and listing of tests almost 40 years ago; however, this exemption may no longer…
- 52If you mention a “401(k),” everyone knows you’re talking about a retirement savings plan. But few people know that the name refers to the U.S. Code of Federal Regulations (CFR), Title 26, Subtitle A, Chapter 1, Subchapter D, Part I, Subpart A, Section 401(k) of the laws governing the Internal Revenue Service.… And if you…